Merck is increasing its HPV vaccine production capacity, but it still won't be enough to meet the full demand in China, a company spokesperson said.

There aren’t any vaccines against the painful viral infection chikungunya, but with new phase 2 results, Themis is one step closer to changing that.

Merck's RotaTeq won China approval in April and a launch is underway, but meanwhile, the company is reducing its shipments to low-income countries.

GlaxoSmithKline's Shingrix is propelling growth at the drugmaker, but tight supply might limit its expansion in the near term.

Here is some other vaccine news of note for the week.

The FDA put Sanofi's Dengvaxia, the dengue vaccine at the center of a safety scandal this year in the Philippines, on its priority track for approval.

The Institut Pasteur spinoff hopes its anti-telomerase cancer vaccine could be useful in immuno-oncology combo therapies.

Merck's Gardasil generated $1 billion in Q3, prompting an analyst to wonder just how much the shot might be able to generate in the long run.